Navigation Links
Current HPV vaccine may not help some women with immune problems
Date:4/7/2013

WASHINGTON, DC (April 7, 2013)Women with HIV acquire cancer-causing forms of the human papillomavirus (HPV) that are not included in the current HPV vaccines Gardasil and Cervarix, according to new research from Fox Chase Cancer Center being presented at the AACR Annual Meeting 2013 on Sunday, April 7.

"People with issues in their immune system such as HIV will be at risk of acquiring HPV, as well and the current vaccine may not fully protect them," says study author Elizabeth Blackman, MPH, research specialist at Fox Chase.

Women who had been taking HIV medications for at least 4 years, however, were less likely to carry cancer-causing forms of HPV, suggesting that treating HIV may also protect women from the consequences of HPV. "Protecting the immune system may prevent other diseases," says Blackman.

More than 40 types of HPV can infect the genital areas and at least 15 of these types are considered "high risk," meaning they can cause changes in cells that can lead to cancer. In the U.S., approximately 4,000 women die each year from cervical cancer, which almost always stems from HPV infection.

But HPV is very commonpractically every sexually active person will acquire it at some point. In most cases, these infections do not lead to cancer, says Blackman, because a healthy immune system can normally clear the virus on its own. "But if your immune system is compromised, such as in HIV, you will not be able to fight off the infection," she says. "Over time, persistent infection with HPV can lead to cancer."

During the study, Blackman and her colleagues tested 176 HIV-positive women living in the Bahamas for the presence of high risk forms of HPV. They chose this population, she explains, because different strains of HPV are prominent in different geographic regions.

Around three-quarters of the women tested carried high-risk forms of HPV and approximately 30% had precancerous cervical cells, as well. The
'/>"/>

Contact: Diana Quattrone
diana.quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Global burden of dengue is triple current estimates
2. d'Oliveira & Associates Issues New Infographic on Xarelto Providing Current FDA and Medical Study Information
3. Current and past smokers face greater risk for hip replacement failure
4. About 15 percent of patients with Wolfram syndrome do not meet current diagnostic criteria
5. Lung Cancer Asbestos Victims Center Now Urges Current Lung Cancer Victims Who Were Exposed to Asbestos at Work to Call Them About What Might be Significant Compensation
6. 5-ALA fluorescence guides resection of recurrent glioblastoma multiforme
7. d’Oliveira & Associates Issues Webpage With Current Information On Mirena IUD Lawsuits
8. Rooting out recurrent breast cancer
9. Study drug is first to help patients with recurrent low-grade ovarian cancer
10. Tomorrows life-saving medications may currently be living at the bottom of the sea
11. d’Oliveira & Associates Releases Webpage With Current Information on Fresenius Lawsuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
(Date:4/24/2014)... Orleans, LA The National Science Foundation has ... Research Experiences for Undergraduates (REU) Site grant in ... the training of undergraduates from diverse social and ... the New Orleans area. The project will ... the summers of 2014-16. It will be ...
(Date:4/24/2014)... research led by a scientist at the University of ... element in the development of the nervous system may ... breast cancer., A research team, led by Dr ... Department of Biology at York, has studied how voltage-gated ... These channels are found in the membranes of excitable ...
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
Breaking Medicine News(10 mins):Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2
... Elsevier announced today that major global ... Germany, has signed an agreement to purchase EMBASE ... first time, EMBASE Classic is a fully digitized ... Journals published between 1947 and 1973. Covering ...
... randomized, controlled, multi-center trial has found that cardiac ... uptake during exercise testing, the trial,s primary endpoint, ... mechanical problems that disrupt the heart,s normal rhythm ... on EKG. , The Resynchronization Therapy in Narrow ...
... OSTE ) announced today that third quarter 2007 revenue ... revenue of $23.4,million. Revenue from Osteotech,s "core" DBM and ... months ended September 30,2007 as compared to revenue of ... of 2006. Gross margin improved to 55% in the ...
... Nov. 6 EntreMed, Inc.,(Nasdaq: ENMD ), ... of cancer and inflammatory diseases, today,reported results for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) Revenues ... $3,023,000 for the comparable period a year ago. ...
... (Pink Sheets: BIEL), announced today that Michael Seidenman,R. ... President of Sales. Mr. Seidenman is a ... versed in electro medicine devices. He brings to,the ... sales,management. Mr. Seidenman has launched many new products, ...
... Nov. 6 /PRNewswire-FirstCall/ - Response Biomedical,Corporation (TSX-V: RBM, ... Stock Exchange (TSX) has conditionally approved the Company,s,application ... Listing on the TSX,will be subject to the ... Company will issue a news release when final ...
Cached Medicine News:Health News:EMBASE Classic makes inroads into pharmaceutical industry 2Health News:Study puts brakes on extending indications for cardiac resynchronization therapy 2Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 2Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 3Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 4Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 5Health News:EntreMed Reports Third Quarter 2007 Financial Results 2Health News:EntreMed Reports Third Quarter 2007 Financial Results 3Health News:EntreMed Reports Third Quarter 2007 Financial Results 4Health News:EntreMed Reports Third Quarter 2007 Financial Results 5Health News:BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales 2Health News:Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange 2Health News:Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange 3
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... and GAITHERSBURG, Md., May 30, 2012   Life Technologies ... OpGen, Inc ., a commercial stage whole genome analysis ... agreement to develop systems, technologies and applications intended to ... the public health and infectious disease markets. ...
... of Opioid Management is presenting the ... the Joseph B. Martin Conference Center at Harvard Medical School. ... clinical application, and compliance, will address the proper use, and ... According to a recent National Survey on Drug Use and ...
Cached Medicine Technology:Life Technologies and OpGen Sign Collaborative Agreement to Leverage Ion Torrent and Whole Genome Mapping Technologies 2Life Technologies and OpGen Sign Collaborative Agreement to Leverage Ion Torrent and Whole Genome Mapping Technologies 3Life Technologies and OpGen Sign Collaborative Agreement to Leverage Ion Torrent and Whole Genome Mapping Technologies 4Unique Conference Tackles Opioid Abuse Epidemic 2
... offers state-of-the-art quality in an instrument of ... durability. Low profile cutting tips allow access ... I instruments are available in just about ... required for large and small joint arthroscopic ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ... style, size and angle required for large ...
... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ... angle required for large and small joint ...
Medicine Products: